BioCryst is profitable. Now it wants to buy more rare disease drugs
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC